Vaccinia viruses defective in the essential gene coding for the enzyme uracil DNA
glycosylase (UDG) do not undergo DNA replication and do not express late genes in wild …

Recombinant vaccinia viruses containing tumor associated genes represent an attractive
vector to induce immune responses to weak immunogens in cancer immunotherapy …

Vaccinia virus has a distinctive history as a vaccine used for the eradication of smallpox, and
the unique biology of this virus has been extensively investigated [1]. Because of its success …

While vectored vaccines, based on hyperattenuated viruses, may lead to new treatment
options against infectious diseases and certain cancers, they are also complex products and …

Publisher Summary This chapter discusses vaccinia virus vectors. With the elimination of a
deadly disease and the eradication of the offending pathogen, the smallpox vaccine holds a …

Vaccinia virus has played a huge part in human beings' victory over smallpox. With smallpox
being eradicated and large-scale vaccination stopped worldwide, vaccinia has assumed a …

Oncolytic vaccinia viruses have made some impressive advances over the last 5 years, with
a range of different backbones displaying significant antitumor responses in preclinical …

Recombinant vaccinia viruses (rVACVs) are promising antigen-delivery systems for vaccine
development that are also useful as research tools. Two common methods for selection …

Introduction Immunotherapy is a rapidly evolving area of cancer therapeutics aimed at
driving a systemic immune response to fight cancer. Oncolytic viruses (OVs) are at the …

Recombinant vaccinia viruses based on the attenuated NYVAC and MVA strains are
promising vaccine candidates against a broad spectrum of diseases. Whilst these vectors …